BIONET Corp. (TPEX:1784)

Market Cap	5.50B
Revenue (ttm)	1.23B
Net Income (ttm)	71.15M
Shares Out	53.12M
EPS (ttm)	1.40
PE Ratio	73.90
Forward PE	n/a
Dividend	1.42 (1.37%)
Ex-Dividend Date	Oct 3, 2025

Volume	2,430,610
Average Volume	893,327
Open	99.80
Previous Close	99.80
Day's Range	99.80 - 109.50
52-Week Range	62.40 - 109.50
Beta	0.43
RSI	79.17
Earnings Date	Nov 11, 2025

About BIONET

BIONET Corp. provides cell therapy services in Taiwan and internationally. The company offers stem cell banking services, including stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and peripheral blood stem cells and immune cells; and genetic testing services. It also provides stem anti-aging and ANIKINE series products; and Exosome, a novel cell-free therapy. In addition, the company offers regenerative medicine, analytical testing, clinical and preclinical research, and commercialized cell-derived...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1989
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 1784

Financial Performance

In 2024, BIONET's revenue was 1.22 billion, an increase of 8.40% compared to the previous year's 1.13 billion. Earnings were 83.70 million, an increase of 6.76%.